2016
Moderate Alcohol Consumption and Chronic Disease: The Case for a Long‐Term Trial
Mukamal KJ, Clowry CM, Murray MM, Hendriks HF, Rimm EB, Sink KM, Adebamowo CA, Dragsted LO, Lapinski PS, Lazo M, Krystal JH. Moderate Alcohol Consumption and Chronic Disease: The Case for a Long‐Term Trial. Alcohol Clinical And Experimental Research 2016, 40: 2283-2291. PMID: 27688006, PMCID: PMC5073014, DOI: 10.1111/acer.13231.Peer-Reviewed Original ResearchConceptsModerate alcohol consumptionChronic diseasesAlcohol consumptionRandomized trialsLong-term clinical trialsCoronary heart diseaseMajor chronic diseasesStrong epidemiological associationLong-term trialsGold standard evidenceNutritional interventionHeart diseaseClinical trialsBreast cancerEpidemiological associationModerate drinkingYears durationClinical investigatorsBiological mediatorsAvailable evidenceDiseaseObserved associationsTrialsStandard evidenceVariety of settings
2011
Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia
Rosenheck RA, Krystal JH, Lew R, Barnett PG, Thwin SS, Fiore L, Valley D, Huang GD, Neal C, Vertrees JE, Liang MH. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia. Clinical Trials 2011, 8: 196-204. PMID: 21270143, DOI: 10.1177/1740774510392931.Peer-Reviewed Original ResearchConceptsSchizo-affective disorderAntipsychotic medicationUsual careMedication adherenceEffectiveness trialCommon co-morbid illnessesCo-morbid illnessHigh-risk patientsComparative effectiveness trialClinical effectiveness trialVeterans Health AdministrationNew antipsychotic medicationsTreatment of schizophreniaPsychiatric inpatient hospitalizationQuality of lifeHealth care costsElectronic medical recordsLong-term trialsPatient's psychiatristPrimary endpointSecondary endpointsFirst hospitalizationRecent hospitalizationInjectable risperidoneUnstable patients